News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
A collage of Michael Klichinsk and Carisma Therapeutics
Jun 27, 2024, 12:32

Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525

Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn:

“We are excited to share that Carisma Therapeutics received FDA Fast Track Designation for CT-0525 for the treatment of advanced HER2-overexpressing solid tumors.

More information here.”

Source: Michael Klichinsky/LinkedIn

cancer Carisma Therapeutics CT-0525 FDA HER2 Michael Klichinsky OncoDaily Oncology solid tumors
Insight
Jun 29, 2024, 15:06
Pavlos Msaouel: Excited for the synergies with The V Foundation, Rare Cancer Research Foundation and Pattern.org to accelerate rare cancer discoveries
Insight
Jun 29, 2024, 15:03
IO inductive therapy let 25% unresectable stage 3 NSCLC become resectable
Blog
Jun 29, 2024, 15:00
Aditya S. Pandey: I am thrilled to welcome Dr. Noojan Kazemi to the Michigan Neurosurgery family
Blog
Jun 29, 2024, 14:56
Ben Garcia: WUSM Biochemistry and Molecular Biophysics Department will be having a junior faculty search this coming fall
Blog
Jun 29, 2024, 14:51
Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI
Opinion
Jun 29, 2024, 14:47
Peter O’Dwyer is taking part in the White House Office Clinical Trials Forum
Societies
Jun 29, 2024, 14:42
María Natalia Gandur Quiroga: Key Takeaways from APCCC 2024
Career
Jun 29, 2024, 14:34
Thordur Oskarsson received the exceptional project grant from Breast Cancer Alliance for breast cancer research - Moffitt Cancer Center
Insight
Jun 29, 2024, 14:29
New risk assessment by Deborah Siegal at ISTH2024
Blog
Jun 29, 2024, 14:26
QUANTRO Therapeutics Achieves Milestone with Boehringer Ingelheim in Developing First-in-Class Cancer Treatments
Societies
Jun 29, 2024, 14:24
KRAS - the most commonly mutated oncogene in cancer
Blog
Jun 29, 2024, 14:20
Kimberley Neve at Cancer Prevention Research Conference